Lornoxicam - 8 mg 20 Tablets

Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, articular syndrome with exacerbation of gout, bursitis, tendovaginitis.

Moderate and severe pain syndrome (including arthralgia, myalgia, neuralgia, lumbago, sciatica, migraine, toothache and headache, algodismenorrhea, pain in trauma, burns. Febrile syndrome (with colds and infectious diseases).

Tradename: Lornoxicam

Lornoxicam

Composition: Each tablet contains:

Lornoxicam 8 mg

Auxiliary components:

Povidone K80, magnesium stearate, lactose monohydrate, microcrystalline cellulose, croscarmellose sodium.

Properties: NSAIDs, belongs to the class of oxicams. It has a pronounced anti-inflammatory and analgesic effect, and also has an antipyretic and antiplatelet effect.

The mechanism of action is associated with the suppression of inflammatory factors; inhibition of prostaglandin synthesis due to inhibition of COX1 and COX2, which leads to disruption of the metabolism of arachidonic acid and inhibition of prostaglandin synthesis both in the focus of inflammation and in healthy tissues. Suppresses the exudative and proliferative phases of inflammation.

Indications: Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, articular syndrome with exacerbation of gout, bursitis, tendovaginitis.

Moderate and severe pain syndrome (including arthralgia, myalgia, neuralgia, lumbago, sciatica, migraine, toothache and headache, algomenorrhea, pain in trauma, burns. Febrile syndrome (with colds and infectious diseases).

Method of administration and dosage: Inside, 8 mg. With an insufficient analgesic effect at a dose of 8 mg, another 8 mg can be taken repeatedly.

The maximum daily dose: when taken orally — 16 mg.

Contraindications: Acute bleeding from the gastrointestinal tract, gastric ulcer and duodenal ulcer in the exacerbation phase, ulcerative colitis in the exacerbation phase, bronchial asthma, severe chronic heart failure, hypovolemia, blood clotting disorders (including hemophilia, hemorrhagic diathesis, thrombocytopenia), severe hepatic and / or renal failure, deficiency of glucose-6-phosphate dehydrogenase, cerebral hemorrhage (including suspicion), pregnancy, lactation, children and adolescents under 18 years of age, hypersensitivity to lornoxicam, acetylsalicylic acid or other NSAIDs.

Precautionary measures: Use with caution in case of erosive and ulcerative lesions and bleeding from the gastrointestinal tract (in history), moderate renal failure, conditions after surgery, in elderly patients (over 65 years old), in patients weighing less than 50 kg.

Lornoxicam should be used only after a careful assessment of the expected benefits of therapy and the possible risk in the following cases: a slight degree of impaired renal function (serum creatinine level 150-300 μmol / l); heart failure and other conditions, accompanied by a decrease in BCC and renal blood flow; liver dysfunction; arterial hypertension and conditions accompanied by fluid retention, edema; patients who have undergone major surgery.

In patients with impaired renal function during the treatment period, regular monitoring of renal function is required.

Since lornoxicam reduces the rate of psychomotor reactions, during the period of application, special care should be taken when driving and other potentially hazardous activities.

Side effects: Acute bleeding from the gastrointestinal tract, gastric ulcer and duodenal ulcer in the exacerbation phase, ulcerative colitis in the exacerbation phase, bronchial asthma, severe chronic heart failure, hypovolemia, blood clotting disorders (including hemophilia, hemorrhagic diathesis, thrombocytopenia), severe hepatic and / or renal failure, deficiency of glucose-6-phosphate dehydrogenase, cerebral hemorrhage (including suspicion), pregnancy, lactation.

Storage method: Store at a temperature not exceeding 30 degrees.

Package: The cardboard box contains 2 blisters of 10 tablets, paper instructions.